OBJECTIVES: We have previously shown that stromal cell-derived factor-1α (SDF-1α) is downregulated within diabetic cutaneous wounds, and that direct application of recombinant SDF-1α increases wound closure rates, neovascularization, and endothelial progenitor cell (EPC) recruitment. However, increased wound levels of exogenous SDF-1α results in elevated systemic levels of this proangiogenic chemokine that raises concerns for tumorigenesis and inflammation. We now seek to test the efficacy of a novel, safer cell-based therapy (CBT) employing ex vivo primed bone marrow-derived stem cells (BMDSC) with SDF-1α. We also elucidate the mechanism of action of this new approach for accelerating diabetic wound healing. METHODS: Unfractionated BMDSC from diabetic Lepr mice were incubated for 20 hours with SDF-1α (100 ng/mL) or bovine serum albumin (control). Pretreated BMDSC (1 × 10) were injected subcutaneously into full-thickness skin wounds in Lepr mice (n = 8 per group). Wound closure rates, capillary density, and the recruitment of EPC were assessed with serial photography, DiI perfusion, confocal microscopy, and immunohistochemistry. The expression of molecular targets, which may mediate prohealing/proangiogenic effects of SDF-1α-primed BMDSC was evaluated by polymerase chain reaction array and immunoblotting assay. The biological function of a potential mediator was tested in a mouse wound-healing model. Serum SDF-1α levels were measured with enzyme-linked immunosorbent assay (ELISA). RESULTS: SDF-1α-primed BMDSC significantly promote wound healing (P < 0.0001), neovascularization (P = 0.0028), and EPC recruitment (P = 0.0059). Gene/protein expression studies demonstrate upregulation of Ephrin Receptor B4 and plasminogen as downstream targets potentially mediating the prohealing and proangiogenic responses. Ex vivo BMDSC activation and the subsequent inoculation of cells into wounds does not increase systemic SDF-1α levels. CONCLUSIONS: We report a novel CBT that is highly effective in promoting healing and neovascularization in a murine model of type 2 diabetes. Furthermore, we identify new molecular targets that may be important for advancing the field of wound healing.
OBJECTIVES: We have previously shown that stromal cell-derived factor-1α (SDF-1α) is downregulated within diabetic cutaneous wounds, and that direct application of recombinant SDF-1α increases wound closure rates, neovascularization, and endothelial progenitor cell (EPC) recruitment. However, increased wound levels of exogenous SDF-1α results in elevated systemic levels of this proangiogenic chemokine that raises concerns for tumorigenesis and inflammation. We now seek to test the efficacy of a novel, safer cell-based therapy (CBT) employing ex vivo primed bone marrow-derived stem cells (BMDSC) with SDF-1α. We also elucidate the mechanism of action of this new approach for accelerating diabetic wound healing. METHODS: Unfractionated BMDSC from diabetic Leprmice were incubated for 20 hours with SDF-1α (100 ng/mL) or bovine serum albumin (control). Pretreated BMDSC (1 × 10) were injected subcutaneously into full-thickness skin wounds in Leprmice (n = 8 per group). Wound closure rates, capillary density, and the recruitment of EPC were assessed with serial photography, DiI perfusion, confocal microscopy, and immunohistochemistry. The expression of molecular targets, which may mediate prohealing/proangiogenic effects of SDF-1α-primed BMDSC was evaluated by polymerase chain reaction array and immunoblotting assay. The biological function of a potential mediator was tested in a mouse wound-healing model. Serum SDF-1α levels were measured with enzyme-linked immunosorbent assay (ELISA). RESULTS:SDF-1α-primed BMDSC significantly promote wound healing (P < 0.0001), neovascularization (P = 0.0028), and EPC recruitment (P = 0.0059). Gene/protein expression studies demonstrate upregulation of Ephrin Receptor B4 and plasminogen as downstream targets potentially mediating the prohealing and proangiogenic responses. Ex vivo BMDSC activation and the subsequent inoculation of cells into wounds does not increase systemic SDF-1α levels. CONCLUSIONS: We report a novel CBT that is highly effective in promoting healing and neovascularization in a murine model of type 2 diabetes. Furthermore, we identify new molecular targets that may be important for advancing the field of wound healing.
Authors: T Iwaki; A Tanaka; Y Miyawaki; A Suzuki; T Kobayashi; J Takamatsu; T Matsushita; K Umemura; T Urano; T Kojima; T Terao; N Kanayama Journal: J Thromb Haemost Date: 2011-06 Impact factor: 5.824
Authors: Lyndsay V Rhodes; Sarah P Short; Nicole F Neel; Virgilio A Salvo; Yun Zhu; Steven Elliott; Yongkun Wei; Dihua Yu; Menghong Sun; Shannon E Muir; Juan P Fonseca; Melyssa R Bratton; Chris Segar; Syreeta L Tilghman; Tammy Sobolik-Delmaire; Linda W Horton; Snjezana Zaja-Milatovic; Bridgette M Collins-Burow; Scott Wadsworth; Barbara S Beckman; Charles E Wood; Suzanne A Fuqua; Kenneth P Nephew; Paul Dent; Rebecca A Worthylake; Tyler J Curiel; Mien-Chie Hung; Ann Richmond; Matthew E Burow Journal: Cancer Res Date: 2010-12-01 Impact factor: 12.701
Authors: Chantal J N Verkleij; Joris J T H Roelofs; Stefan R Havik; Joost C M Meijers; Pauline F Marx Journal: Thromb Res Date: 2010-09-09 Impact factor: 3.944
Authors: Matthew B Kahn; Nadira Y Yuldasheva; Richard M Cubbon; Jessica Smith; Sheikh T Rashid; Hema Viswambharan; Helen Imrie; Afroze Abbas; Adil Rajwani; Amir Aziz; Vivek Baliga; Piruthivi Sukumar; Matthew Gage; Mark T Kearney; Stephen B Wheatcroft Journal: Diabetes Date: 2011-02-11 Impact factor: 9.461
Authors: Peter Adam Rees; Nicholas Stuart Greaves; Mohamed Baguneid; Ardeshir Bayat Journal: Adv Wound Care (New Rochelle) Date: 2015-11-01 Impact factor: 4.730
Authors: Jordan D Skelly; Jeffrey Lange; Tera M Filion; Xinning Li; David C Ayers; Jie Song Journal: Clin Orthop Relat Res Date: 2014-08-07 Impact factor: 4.176
Authors: Marinko Sremac; Ji Lei; Madeline F E Penson; Christian Schuetz; Jonathan R T Lakey; Klearchos K Papas; Pushkar S Varde; Bernhard Hering; Paul de Vos; Timothy Brauns; James Markmann; Mark C Poznansky Journal: Transplant Direct Date: 2019-04-15